MarketPulse

stock price decline

515 articles
BenzingaBenzinga··Law Offices Of Frank R. Cruz

Driven Brands Plunges 30% on Accounting Fraud Disclosure; Class Action Filed

Driven Brands disclosed material accounting errors spanning 2023-2026, including improper revenue recognition and cash discrepancies. Stock crashed 30.2% to $11.60, triggering shareholder litigation.
DRVNsecurities fraudclass action lawsuit
BenzingaBenzinga··Law Offices Of Howard G. Smith

IperionX Stock Plunges 16% on Accounting Error; Securities Fraud Probe Launched

IperionX stock tumbled 16% after disclosing a typographic error in financial reporting, prompting a securities fraud investigation into the specialty materials company.
IPXsecurities fraudinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Two Major Securities Class Actions Target BlackRock TCP and Plug Power Over Disclosure Failures

Law firm pursues class actions against BlackRock TCP and Plug Power for alleged disclosure violations, citing NAV misstatements and misrepresented loan prospects.
PLUGTCPCsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kessler Topaz Meltzer & Check, Llp

uniQure Hit With Securities Fraud Suit Over Gene Therapy Misstatements

Class action lawsuit filed against $QURE over alleged misstatements about Huntington's disease therapy approval timeline. Stock crashed 49% after FDA stance shift.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

AQST Stock Plunged 37% After FDA Setback; Securities Lawsuit Deadline Looms May 4

Aquestive Therapeutics faces securities class action over alleged false FDA approval statements for Anaphylm drug. Stock fell 37% after January 2026 NDA rejection.
AQSTsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Camping World Holdings Faces Securities Lawsuit Over Inventory Claims

Securities class action filed against $CWH for allegedly misleading statements on inventory management. Stock fell sharply in Q3-Q4 2025; investor deadline set for May 11, 2026.
CWHsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Nektar Therapeutics Hit With Securities Class Action Over Failed Trial Disclosures

Nektar faces securities litigation over alleged misstatements about REZOLVE-AA trial enrollment practices. Stock fell 7.77% after trial failure announcement.
NKTRsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Energy Storage Firm EOSE Faces Securities Suit Over Major Revenue Miss

Eos Energy Enterprises faces securities class action over $35.8M revenue shortfall, missing 2025 guidance by 24-30%. Stock fell 39.4%; investors have until May 5, 2026 to join suit.
EOSEguidance misssecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Ultragenyx Stock Tumbles on Failed Drug Trials; Class Action Deadline Looms

Securities class action filed against $RARE over alleged misstatements about setrusumab drug efficacy. Failed clinical trials triggered 25-42% stock declines. Investor deadline: April 6, 2026.
RAREsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Geller Rudman & Dowd Llp

Navan Faces Securities Lawsuit Over Concealed Marketing Spending Surge

Navan investors sue over allegedly misleading IPO disclosures. Stock crashed 63% after surprise 39% sales expense hike revealed.
NAVNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Geller Rudman & Dowd Llp

Driven Brands Faces Class Action Over $DRVN Financial Restatement; Stock Plummets 40%

Driven Brands ($DRVN) faces class action lawsuit over accounting errors in fiscal 2023-2025 statements. Stock fell 40% after February disclosure. Investors can seek lead plaintiff status.
DRVNsecurities fraudclass action lawsuit
BenzingaBenzinga··The Law Offices Of Frank R. Cruz

IperionX Stock Plunges 16% After $17.7M Accounting Error Sparks Fraud Investigation

$IPX crashed 16% after disclosing a $17.7M carrying amount misstatement in financial reports. Securities fraud investigation launched for affected shareholders.
IPXsecurities fraudinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

ODDITY Tech Stock Crashes 49% After Disclosure of Hidden Ad Partner Algorithm Changes

ODDITY Tech faces class action lawsuit alleging concealment of ad partner algorithm changes that inflated customer acquisition costs. Stock fell 49% after CEO disclosure on February 25.
ODDsecurities fraudclass action lawsuit
BenzingaBenzinga··Law Offices Of Howard G. Smith

DRVN Plummets 30% After Accounting Restatement; Class Action Deadline Looms

Driven Brands ($DRVN) stock plummets 30.2% after disclosing multi-year accounting errors. Class action deadline set for May 8, 2026.
DRVNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kessler Topaz Meltzer & Check, Llp

Kyndryl Faces Securities Fraud Suit Over Control Failures; Stock Crashed 54%

Kyndryl ($KD) faces class action lawsuit alleging material misstatements on controls. Stock plunged 54% after CFO, General Counsel departures and SEC disclosure.
KDsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

$TCOM Faces Securities Fraud Lawsuit Over Concealed Antitrust Risks

Trip.com faces securities fraud class action for allegedly understating regulatory risks. Stock fell 17% after China's antitrust investigation was revealed in January 2026.
TCOMsecurities fraudregulatory risk
BenzingaBenzinga··Business Wire

Driven Brands Faces Securities Fraud Suit Over $11.6B Financial Restatement

Driven Brands faces securities fraud class action over material accounting errors spanning 2023-2026. Stock fell 30.2% following disclosure.
DRVNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

Eos Energy Stock Plummets 39% After Missing Revenue Guidance by $36M

Eos Energy stock drops 39% after missing $150-160M guidance with $114.2M revenue. Securities fraud lawsuit filed by Glancy Prongay Wolke & Rotter.
EOSEsecurities fraudclass action lawsuit
BenzingaBenzinga··Business Wire

Nektar Therapeutics Faces Securities Fraud Investigation After Failed Trial Announcement

Law firm investigates $NKTR over December trial failure disclosure. Stock dropped 7.8% after alopecia areata Phase 2b study missed endpoints due to ineligible patients.
NKTRshareholder lawsuitstock price decline
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

Ultragenyx Stock Collapses 42% After Clinical Trial Failure, Class Action Deadline Looms

Ultragenyx Pharmaceutical's stock plunged 42% after failing to disclose setrusumab Phase 3 trial failure, triggering securities litigation with April 6, 2026 lead plaintiff deadline.
RAREsecurities fraudclass action lawsuit